BioSpace News Archive

Boehringer Ingelheim announced today that Dr. Wolfgang Baiker , U.S. Country Managing Director, President and CEO, will retire after 31 years of committed service to the company on July 31, 2020 . Jean-Michel Boers has been appointed to succeed him.

MedRhythms announced that it has received Breakthrough Device designation from the U.S. Food and Drug Administration for its patented digital therapeutic to treat chronic stroke walking deficits.

Loki Therapeutics, an immuno-oncology company developing next-generation cancer therapeutics that leverage childhood vaccination recall antigens, today announced the formation of its Scientific Advisory Board (SAB), and the appointment of several prominent members, including Eileen O’Reilly , MD, of Memorial Sloan Kettering C

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (“4Front” or the “Company”) today announced its audited financial results for the fourth quarter and Fiscal Year 2019 and preliminary results for the First Quarter of 2020.

Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the appointment of Marie-Louise Fjällskog, M.D., Ph.D., as Chief Medical Officer, responsible for leading clinical and development strategy and operations. Dr. Fjällskog joins Sensei from Merus, where she served as Vice President Clinical Development and led the developme

Pharmacy Quality Solutions (PQS), the leading technology provider of pharmacy performance management services, and leading health and well-being company, Humana (NYSE: HUM), have partnered on a new diabetes outcomes-based pilot program that will be hosted within PQS’s EQuIPP® platform.

Codiak to Present New Preclinical Data on exoASO™-STAT6 and exoASO-C/EBPβ at the AACR 2020 Virtual Annual Meeting

Foundation Medicine, Inc., today announced the appointment of Dr. Geoffrey R. Oxnard as vice president, global medical lead for the Company’s liquid biopsy portfolio, effective immediately.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported the success of its initiative to conduct safe patient screenings remotely using telehealth technologies.

Building on Merck for Mothers’ Efforts, Initiative Bolsters Support for Locally Created Solutions to Improve Maternal Health and Narrow Disparities During the COVID-19 Pandemic and Beyond KENILWORTH, N.J.--( BUSINESS WIRE )-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today it was expanding its Safer Childbirth Cities initiative, a multi-year effort to improve U.S. maternal health outcomes. Safer Childbirth Citie